ZIOP from JPM a little bit of go. Q&A "Very encouraged through today IL-12 Glioma - patients since June - PFS weeks - months to death - but these patients are doing well....working with FDA....
Second cohort....we can share data - major inflection point at ASCO....very encourgaged....checkpoint inhibitors not working well....so this is key - MD Anderson single center trial also coming
Dose escalation - quite confident we will get permission from Data Monitoring - we are now accelerating recruitment...- confident enough data to accelerate recruitment
Level of interest in this Glioma trial VERY HIGH - we have had to turn down patients...we are VERY optimistic.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.